Post-operative cardiac surgery patients on mechanical ventilation
Conditions
Interventions
Experimental group1:Remimazolam besylate 0.1mg/kg/h
Experimental group2:Remimazolam besylate 0.15mg/kg/h
Experimental group3:Remimazolam besylate 0.2mg/kg/h
Experimental group4:Remimazolam besylate 0.25mg/kg/h
Experimental group5:Remimazolam besylate 0.3mg/kg/h
Sponsors
Beijing Anzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years; 2. post-operative cardiac surgery mechanical ventilation requiring analgesic sedation and expected to require mechanical ventilation for >=12 hours and = 40%; 4. obtain informed consent from the patient or family.
Exclusion criteria
Exclusion criteria: 1. Pregnancy or breastfeeding; 2. Severe, existing substantial liver disease with clinically significant portal hypertension, Child-Pugh C cirrhosis or acute liver failure; 3. Patients with acute and chronic renal insufficiency requiring dialysis; 4. Bronchial asthma or COPD, myasthenia gravis patients; 5. Patients with a history of alcohol or drug abuse; 6. Long-term oral sedative, anti-insomnia, anti-anxiety drugs 7. Patients who take long-term immunosuppressants or hormones; 8. There are symptoms of delirium and alcohol withdrawal; 9. Patients with severe pulmonary hypertension combined with Eisenmenger syndrome; 10. Circulatory or hemodynamic instability requires supporters of mechanical devices such as ECMO and IABP; 11. Severe craniocerebral injury, brain tumor, increased intracranial pressure, cerebrovascular accident, coma, status epilepticus; 12. Any condition that prevents the correct assessment of cognitive function, such as language and sensory disturbances or psychiatric disturbances (language difficulties or psychoorganic dysfunction); 13. Allergy to the research drug or other contraindications; 14. The patient himself or his legally authorized representative is unwilling to sign the informed consent; 15. There are factors that increase the risk associated with participating in the study (such as the presence of severe hypotension), which is not suitable for inclusion in the study according to the investigator's judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective dose of remimazolam besylate for sedation of mechanically ventilated patients in the Intensive Care Unit after cardiac surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse cardiovascular events; | — |
Countries
China
Contacts
Public ContactHou Xiaotong
Beijing Anzhen Hospital
Outcome results
None listed